Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Recurrent Ovarian Carcinoma
Interventions: DRUG: Ribociclib|DRUG: Belinostat
Sponsor: University of Utah
Collaborators: Novartis|Acrotech Biopharma